These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12643119)

  • 1. The use of ACE inhibitors on diabetic patients without renal disease.
    Kirpichnikov D; Winer N; Sowers JR
    Curr Diab Rep; 2002 Feb; 2(1):21-5. PubMed ID: 12643119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of ACE inhibitors in diabetes: from theory to therapeutic management.
    Yudkin JS
    J Diabetes Complications; 1996; 10(3):129-32. PubMed ID: 8807456
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction.
    Abbott KC; Bakris GL
    Prog Brain Res; 2002; 139():289-98. PubMed ID: 12436944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients.
    So WY; Ozaki R; Chan NN; Tong PC; Ho CS; Lam CW; Ko GT; Chow CC; Chan WB; Ma RC; Chan JC
    Hypertension; 2004 Sep; 44(3):294-9. PubMed ID: 15249544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
    Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
    Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the renin-angiotensin system: added value in reducing cardiovascular and renal risk?
    Marshall SM
    Diabet Med; 2004 Jan; 21(1):1-3. PubMed ID: 14706047
    [No Abstract]   [Full Text] [Related]  

  • 7. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.
    Silverstein RL; Fenves AZ; Ram CV
    Postgrad Med; 2004 Aug; 116(2):31-8, 41. PubMed ID: 15323152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease.
    Mogensen CE
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):234-9. PubMed ID: 11881030
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
    Gerstein HC
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ACE inhibitors in treating hypertensive diabetic patients.
    Kirpichnikov D; Sowers JR
    Curr Diab Rep; 2002 Jun; 2(3):251-7. PubMed ID: 12643181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus.
    Nosadini R; Abaterusso C; Dalla Vestra M; Bortoloso E; Saller A; Bruseghin M; Sfriso A; Trevisan M
    Nephrol Dial Transplant; 1998; 13 Suppl 8():44-8. PubMed ID: 9870425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diabetic nephropathy and ACE inhibitors].
    Amann B
    Clin Res Cardiol; 2006 Jan; 95 Suppl 1():i83-7. PubMed ID: 16598556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
    Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
    PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
    Studney D
    Can J Cardiol; 2002 May; 18 Suppl A():3A-6A. PubMed ID: 12045787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing end-stage renal disease.
    Mogensen CE
    Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Burnier M; Zanchi A
    J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C; Schernthaner G
    Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.
    Gerstein HC; Bosch J; Pogue J; Taylor DW; Zinman B; Yusuf S
    Diabetes Care; 1996 Nov; 19(11):1225-8. PubMed ID: 8908384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.